Mutations in the epigenetic regulator gene EZH2 are frequently observed in patients with myelodysplastic/myeloproliferative neoplasms (MDS/MPN; 10-13%) and are associated with a poor outcome. To gain more insight into EZH2 pathology, we sought to genetically characterize a cohort of 41 EZH2-mutated MDS/MPN patients using targeted deep next-generation sequencing (NGS), colony-forming progenitor assays and transcriptome analysis. Stable short hairpin RNA (shRNA)-mediated downregulation of EZH2 was performed in MDS-derived F-36P, MOLM-13 and OCI-M2 cells to study EZH2-specific changes. Targeted NGS revealed a complex pattern of mutations with a total of 190 individual mutations. EZH2 mutations frequently co-occur with TET2 (58%), RUNX1 (40%) and ASXL1 (34%) mutations. Colony assays indicated EZH2 mutations to be mostly early events in leukemogenesis and showed a complex mutational hierarchy. Gene expression data revealed a number of differently expressed genes between EZH2 wild-type and mutant patients including known EZH2 targets. Comparison of patient transcriptome to EZH2-downregulated cell line data revealed several genes as novel EZH2 targets, showing opposite as well as unidirectional regulation between cell lines and patients. Some genes, such as CXXC5, ETS1 and VAV3 have previously been implied to have a role in leukemogenesis. Their precise role in MDS/MPN needs to be further investigated.
INTRODUCTION
Discoveries like BCR-ABL1 in chronic myeloid leukemia 1 and JAK2-V617F in polycythemia vera 2 have shown that single molecular aberrations can bring about a better understanding of a disease entity and aid classification and treatment. 3, 4 However, in recent years, through advances in sequencing technology, particularly next-generation sequencing (NGS), the ongoing effort to better define the molecular background of myeloid malignancies has revealed a perhaps unexpected complexity. A large number of somatic mutations affecting multiple pathways have been identified with varying frequencies and combinations that overlap the different disease entities. 5 Originally, aberrations were discovered in genes that confer a growth advantage by altering signaling pathways and expression of key transcriptional targets. 6 Over time, additional pathways such as epigenetic modification, RNA splicing, and as recently discovered the cohesin complex, in particular STAG2, were found to be involved in myeloid leukemogenesis. 5, 7, 8 The task at hand is to unravel these heterogeneous molecular patterns and hierarchies, to study their effects on disease phenotype and ultimately to identify new therapeutic targets. Epigenetic targeted therapy is of particular interest because epigenetic changes-unlike somatic gene mutations-are potentially reversible and offer promising therapeutic alternatives even in elderly patients. 9 This study focuses on myeloproliferative/myelodysplastic neoplasms (MDS/MPN) in adults, as this overlap category encompasses both the dysplastic and the hyperproliferative features seen in other myeloid malignancies. Chronic myelomonocytic leukemia (CMML) is the most common entity in this category with a heterogeneous genetic background that is reflected in the diverse clinical and pathological features of this disease. Other diseases in the MDS/MPN category show a similar complexity and include BCR-ABL1-negative atypical chronic myeloid leukemia (aCML), MDS/MPN, unclassifiable (MDS/MPN-U) and juvenile myelomonocytic leukemia. 3 Among the most frequently mutated signaling genes in MDS/ MPN are CBL (8-20%), KRAS (7-11%), NRAS (4-30%) and SETBP1 (6-25%). Aberrations of components of the RNA splicing machinery are common, most frequently involving SRSF2 with mutations detectable in 36-46% of CMML patients and less frequently involving U2AF35 (5-15%) and ZRSR2 (8-10%). RUNX1, which encodes a transcription factor involved in cell growth, survival and differentiation is mutated in 6-20% of MDS/MPN cases. Thirty to 60% of patients show TET2 mutations and less than 10% DNMT3A and IDH1/2 mutations, all of which impair DNA methylation. Other epigenetic changes affecting histone modifications are frequently detected in ASXL1 (20-44%) and EZH2 (6-13%).
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EZH2 is an epigenetic regulator gene encoding the catalytic subunit of the polycomb repressive complex 2 (PRC2), a histone H3 lysine 27 (H3K27) methyltransferase. Overexpression of this gene has previously been observed in prostate, breast and bladder cancer among others. 10 Remarkably, loss-of-function mutations have been detected in myeloid malignancies, highlighting the ambiguous role of EZH2 in cancer. Such mutations are associated with poor overall and progression-free survival and occur most frequently in the MDS/MPN category (10-13%).
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In light of these findings, we aimed to genetically characterize a cohort of 41 EZH2-mutated MDS/MPN patients to investigate mutational patterns associated with EZH2. To better understand the complex clonal hierarchies of detected mutations, colony assays were carried out. In addition, to investigate the effect of loss-of-function EZH2 mutations on gene expression, we carried out whole transcriptome analysis on a subset of our patient cohort compared with EZH2 wild-type MDS/MPN patients. To identify specific EZH2 targets, we compared the results with cell lines F-36P, MOLM-13 and OCI-M2, where suppression of EZH2 translation was achieved by stable transduction of EZH2-targeting short hairpin RNAs (shRNAs).
MATERIALS AND METHODS Patients
The bone marrow samples were collected from 41 EZH2-mutation-positive MDS/MPN patients (CMML, n = 25; aCML, n = 11; MDS/MPN-U, n = 5; male, n = 25). Patients were classified according to the 2008 WHO classification of myeloid neoplasms and acute leukemia. 3 The bone marrow samples of a cohort of 12 EZH2 wild-type MDS/MPN patients (A-L; male, n = 9) were used as a control group. Clinical information is given in Supplementary  Table 1 . The study has been approved by the institutional ethics committee and written informed consent was provided according to the Declaration of Helsinki.
Sample preparation
Total bone marrow leukocytes were isolated after erythrocyte lysis according to standard protocols. Leukocyte RNA extraction was performed using TRIzol reagent, as described previously. 12 Genomic DNA from leukocytes was extracted using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's guidelines. Mononuclear cells were isolated according to standard procedures using Ficoll density gradient centrifugation, and CD34+ selected by MACS separation with the CD34 MicroBead Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer's instructions.
Next-generation sequencing NGS, including data analysis was performed for 30 leukemia-associated target genes on the 454 GS Junior platform with 454 GS Junior Titanium chemistry for amplicon sequencing (Roche Diagnostics, Basel, Switzerland) as previously described. 13, 14 In total, 231 amplicons were prepared for each sample and processed in a single NGS run. Mutations with a frequency 415% were confirmed using Sanger sequencing with standard techniques on an ABI 3500 Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA, USA) as described previously.
14 DNA-sequencing raw data are available on reasonable request.
Colony assays and sanger sequencing
Cryoconserved CD34+ cells of patients #24, 37, 40 and 41 were plated and processed for analysis by colony assay as previously described. 15 To check the specific mutational status of individual colonies, Sanger sequencing of PCR products covering the relevant genetic regions was performed according to standard techniques.
14 Mutational analysis was performed using the Mutation Surveyor software (SoftGenetics, State College, PA, USA). A dropping factor (drop in height of the normal peak at the position of the mutation relative to the neighboring peaks) of o 30% was considered indicative of wild type, a dropping factor between 30 and 70% was considered to be a heterozygous mutation and a factor 470% was considered to be homozygous.
Stable shRNA-mediated downregulation of EZH2 Two shRNA encoding oligonucleotides targeting EZH2 (shEZH2_1: 5′-GAG AGATTATTTCTCAAGATG-3′; shEZH2_2: 5′-TGGAAAGAACGGAAATCTTAA-3′), or a nontargeting control shRNA (Sigma-Aldrich, St Louis, MO, USA) were inserted between AgeI and EcoRI restriction sites into plasmid pLKO.1 (Sigma). Expression constructs were transduced and selected in cell lines F-36P (ACC-543), MOLM-13 (ACC-554) and OCI-M2 (ACC-619), purchased from The Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH, as described previously 16 and tested for mycoplasma contamination. Growth curves of cell lines were generated using the CellTitre-Glo cell viability assay (Promega, Fitchburg, WI, USA), according to the manufacturer's instructions.
Whole transcriptome analysis and qRT-PCR Total RNA (200 ng) of 24 MDS/MPN bone marrow leukocyte samples (n = 12 EZH2-mutated and wild-type cases, respectively) as well as shEZH2_1 and shEZH2_2 downregulated F-36P, MOLM-13 and OCI-M2 cell lines and respective control cells transduced with nontargeting shRNA (four each, collected at four time points) were processed and analyzed as previously described. 17 Control probe quality check, background subtraction, signal averaging and data analysis were performed using Illumina GenomeStudio-Software v.2011.1 (Illumina, San Diego, CA, USA) and GraphPad Prism v6.01 (GraphPad Software, Inc., San Diego, CA, USA). Expression data obtained from EZH2 wild-type vs mutant MDS/MPN patients for genes showing fold change (FC) values ⩾ 2 and signal intensities ⩾ 100, as well as detection P-values o 0.05 in at least one group, to minimize false positive signals, were subjected to statistical analysis (Mann-Whitney test) and compared with F-36P, MOLM-13 and OCI-M2 expression data (Student's t-test). Transcriptome data have been deposited in the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-5766. The results were verified using qRT-PCR according to standard protocols with SYBR-green dye (Roche) and beta glucuronidase (GUSB) as a reference gene. Primer sequences are available in Supplementary Table 2 .
Western blot analysis Protein blot analysis was performed for genes showing average expression signals 4100 in cell lines and patients, using primary antibodies against EZH2 (#3147), histone H3 (#9717), H3K27me3 (#9733), CXXC5 (#84546), ETS1 (#14069), VAV3 (#2398), GAPDH (#2118; Cell Signaling Technology, Boston, MA, USA), FAM133B (HPA043901; Atlas Antibodies, Bromma, Sweden) and STS-1 (ab197027; Abcam, Cambridge, UK). Protein isolation was carried out using 5 × 10 6 cells, according to standard procedures using radioimmunoprecipitation assay buffer (RIPA) with standard protease inhibitors and 100 mM sodium-ortho-vanadate. For each sample, protein lysates were separated, blotted and blocked as previously described. 18 The blots were incubated with the indicated primary antibodies for 16 h at 4°C. After incubation with respective secondary antibodies, chemiluminescent HRP substrate (Millipore, Billerica, MA, USA) was added. The proteins were visualized with ImageQuant LAS-4000 (GE Healthcare, Chicago, IL, USA) and quantified using ImageJ (National Institute of Health, Bethesda, MD, USA).
RESULTS
Cooperating mutations in leukemia-associated genes in 41 EZH2-mutated MDS/MPN patients In total, 190 individual mutations affecting 19 genes were detected, including 53 mutations of EZH2. In addition to EZH2 mutations, 23/41 patients (56%) showed cooperating TET2 mutations, followed by RUNX1 (39%), ASXL1 (34%), CBL (24%), ZRSR2 (20%), SRSF2 (15%), NRAS (15%), STAG2 (12%) and SETBP1 (12%), affecting all five aforementioned pathways. The majority of patients with mutations in TET2, RUNX1 and/or ASXL1 carried frameshift, nonsense or splice site mutations in these genes (83%, 81%, 93%, respectively), which often have severe functional consequences. Multiple mutations in the same gene were most commonly observed in TET2 with 16/23 (70%) affected patients showing up to three mutations. Approximately 30% of affected patients carried multiple mutations in EZH2, RUNX1 and CBL (Figure 1 ). Detailed DNA-sequencing data is given in Supplementary Table 3 . As some mutations were located on the same amplicon, biallelic mutations could be distinguished from monoallelic mutations. Biallelic mutations were detected in patients #4 (CBL), 13 (CBL) and 26 (TET2), whereas patients #30 (RUNX1) and 40 (EZH2) carried monoallelic mutations and patient 
Clonal hierarchies of patients #24, 37, 40 and 41
The analysis of 216 individual colonies for mutations detected by NGS revealed various mutational patterns. The detection of clones carrying only EZH2 mutations in patients #37 and 40 indicates that EZH2 precedes the acquisition of SETBP1 mutations, followed by mutations of NRAS and CBL, respectively (Figures 2a and b) . In patient #37 the low-level KRAS, RUNX1, STAG2 and ZRSR2 mutations previously detected by NGS were not found in the analyzed colonies. The putative evolutionary tree generated for patient #24 also indicates EZH2 and SETBP1 mutations to be early events in leukemogenesis (Figure 2c ). Overall, a more complex pattern of mutations was detected in this patient, with various subclones, changing from heterozygous to homozygous or wildtype states for certain mutations. Interestingly, colony analysis of patient #41 indicates the early acquisition of an ASXL1 mutation, followed by EZH2 mutations p.T467Hfs*16 and p.Y579X, respectively (Figure 2d ).
Transcriptome analysis of EZH2 wild-type and mutant MDS/MPN patients Initial comparison of transcriptome-wide expression data of EZH2 wild-type and mutant MDS/MPN patients showed clear differences in overall gene expression, particularly for a number of highly expressed genes, albeit not above 2 FC (Figure 3a ). In total, 1375 genes with significant ⩾ 2 FC differences between the EZH2 wild-type and mutant group with average signal intensities above 100 in at least one group were detected. Detailed expression data are given in Supplementary Table 4 . Correlation cluster analysis of patient data showed a distinct separation of expression patterns according to EZH2 status. Heat map data revealed that most EZH2 wild-type MDS/MPN patients displayed higher expression levels in the majority of differently expressed genes (Figure 3b ). Some known EZH2 targets, such as ADRB2 and the NOTCH-and JAK-STAT pathway genes, MYC, JAK1 and JAK2 10 were found to have significantly different expression levels between EZH2 mutant and wild-type patients (Figure 3c ).
Transcriptome analysis of the EZH2-downregulated F-36P, MOLM-13 and OCI-M2 cell lines For each cell line, we compared transcriptome data of genes that showed significant differences between EZH2 wild-type and mutant patients as shown above, to gene expression data of shEZH2-downregulated cell lines with the respective control cell line, expressing nontargeting control shRNA. All cell lines showed significant differences in expression levels for CXXC5 and FAM113B. For F-36P, we found 237 genes that showed P-values o 0.05 for one or both shEZH2-manipulated cell lines. Four of these genes (PM20D2, PRAGMIN, RAB3IL1 and STS-1) showed ⩾ 2 FC, significant differences in both downregulated F-36P lines compared with the control. In MOLM-13, we found 91 genes that showed P-values o0.05 for one or both shEZH2-manipulated cell lines. Two genes (ETS1 and VAV3) showed ⩾ 2 FC, significant differences in both downregulated MOLM-13 lines compared with the control. OCI-M2 cell lines showed 318 genes with P-values o0.05 for one or both manipulated cell lines. Significant differences in expression for both downregulated OCI-M2 lines were seen in VAV3, albeit not ⩾ 2 FC. As seen with patient data, a number of previously identified EZH2 targets 10, 19 showed significant differences in shEZH2-downregulated OCI-M2 lines compared with controls. Detailed expression data is given in Supplementary Table 4. Significant differences in EZH2 expression were only observed in cell lines (Figure 4) , as EZH2 may be expressed but functionally compromised in patients carrying missense mutations. Interestingly, some genes such as CXXC5, ETS1, STS-1 and VAV3 showed opposite directions of regulation in patients compared with cell models, whereas others such as FAM113B and PRAGMIN showed regulation in the same direction. EZH2 dysregulation in MDS/MPN J Rinke et al trimethylation, as a result of impaired EZH2 function. In addition, changes in protein levels of ETS1, STS-1 and VAV3 were detected for respective cell lines. CXXC5 and FAM113B were on the resolution limit of protein blot analysis, but showed differences o2 FC in line with RNA expression data (Figure 5a ). Semiquantified cell line data is shown in optical density charts in Figure 5b . Exemplary patient data showed no EZH2 in patients #27 and 32 as a result of homozygous frameshift mutations (p.K685Rfs*12 and p.K17Sfs*3, respectively). Patients #24 and 34 carry heterozygous frameshift (p.N263Qfs*8) and nonsense mutations (p.Y292X), respectively. Downregulation of H3K27 trimethylation was observed in EZH2 mutant patients #24, 27, 32 and 34 compared with EZH2 wild-type patients D and F though overall EZH2 protein levels were lower (Figure 5c ).
DISCUSSION
NGS of EZH2 mutant MDS/MPN patients revealed various mutational patterns. TET2, RUNX1 and ASXL1 were most frequently mutated together with EZH2, which is in agreement with previous findings. 19 Interestingly, 39% of patients showed RUNX1 mutations ( Figure 1 ). This is in line with recent MDS studies showing a significant association of EZH2 and RUNX1. 20, 21 These studies also reported that EZH2 and SRSF2 are rarely mutated together. We found SRSF2 mutations in only 15% of our patients. Splicing mutations in SF3B1 and U2AF1 did not co-occur with EZH2 mutations or were present at very low levels (2.4%), respectively ( Figure 1 ). Khan et al. 19 have demonstrated that splicing abnormalities are often responsible for loss of EZH2 function. This may explain why splicing mutations occur rarely in EZH2-positive patients, as epistasis or synthetic lethality can cause mutual exclusion of certain gene mutations. 22 However, heterozygous mutations for multiple genes that regulate PRC2 function can cooperate in leukemic transformations through additive effects. 23 Previous findings of EZH2 mutations in patients with refractory anemia, suggest that EZH2 mutations are acquired early in leukemogenesis. 11 Our analysis of clonal hierarchies confirmed that EZH2 mutations can indeed be early events, at least in MDS/ MPN cases harboring additional SETBP1 mutations as seen in patients #24, 37 and 40. In the latter two acquisition of NRAS and CBL mutations occurred last (Figures 2a and b) , supporting previous findings that signaling genes are often affected later on in disease progression. 24 Results showed a clonal architecture with moderate to frequent branching. Particularly patient #24 displayed a complex pattern of disease evolution (Figure 2c) . The progression to homozygous and reversion to wild-type states for certain loci can be explained through loss of heterozygosity and reflect the current view of vast genetic diversity in leukemic cells as opposed to the merely linear acquisition of mutations. 24, 25 In support of this mono-and biallelic, as well as overlapping mutations were detected in some patients (Supplementary Figure 1) . The clonal hierarchy of patient #41 showed EZH2 mutations as secondary events, preceded by the acquisition of an ASXL1 mutation (Figure 2d) . A recent study proposed that CMML arises through accumulation of mostly age-related somatic mutations that ultimately convert a skewed myelomonocytic hematopoiesis into leukemia. 26 In line with these findings, it has been shown that early clonal dominance, particularly of TET2 or ASXL1 mutant myeloid progenitors is followed by selection of clones carrying secondary lesions during myeloid differentiation. 24 Both TET2 and ASXL1 have been implicated in age-related clonal hematopoiesis, thus it is not surprising that they have early key roles in the development of CMML. In contrast, EZH2 (and SETBP1) mutations have not been shown to be involved in age-related clonal hematopoiesis. 26 Thus EZH2 mutations may reflect an alternative mode of MDS/MPN initiation or, in cases where agerelated clonal hematopoiesis genes are involved, could provide the growth advantage that is essential for leukemic transformation. In any case, the total number of mutated genes seems to be a strong prognostic factor in CMML, indicating that clonal complexity might affect therapy. 27 Thus, the delineation of clonal architecture remains of prime importance to ensure therapy is directed at primary lesions.
Whole transcriptome analysis of EZH2 wild-type and mutant MDS/MPN patients showed distinct expression patterns (Figure 3a) , suggesting that the EZH2 mutational status has a global effect on gene expression. Interestingly, EZH2 wild-type patients show most upregulation in differently expressed genes, when looking at cluster correlation analysis (Figure 3b ). These findings underline the complex role of EZH2 as an epigenetic regulator that may silence or activate targets by pathwaydependent mechanisms. As multiple mechanisms can affect H3K27me3, 19 it is not surprising that two patients showed expression patterns distinct from their respective group (Figure 3b ). Looking at known EZH2 targets, 10 we found significant differences in ADRB2, JAK1, JAK2 and MYC between EZH2 wild-type and mutant patients (Figure 3c) . Expression levels of genes related to known EZH2 targets, such as HOXA5, HOXB5 and cyclins A1, A2, B1, D2 and F, were also affected (Supplementary Table 4) . (c) Microarray average signal intensities and Log2 data of known EZH2 targets ADRB2, JAK1, JAK2 and MYC for EZH2 wild-type and mutant patients; *P ⩽ 0.05; **P ⩽ 0.005; ***P ⩽ 0.0005. Detailed information is given in Supplementary Table 4 .
However, it is important to note that MDS/MPN patients show vastly heterogeneous genetic lesions, which is reflected in the large number of differently expressed genes and the clinical heterogeneity of these diseases. Therefore EZH2 knockdown models were established in sAML cell lines F-36P, MOLM-13 and OCI-M2. We found two genes to be regulated in patients and all cell lines (CXXC5, FAM113B), and a number of genes that were regulated in patients and at least one cell line, such as ETS1, STS-1 and VAV3 (Figure 4) . The Wntsignaling inhibitor CXXC5 has a role in myelopoiesis and is a known tumor-suppressor candidate, located on 5q31.2, a region recurrently deleted in AML and MDS. Its downregulation has been associated with a better outcome in AML, pointing towards the potential benefits of Wnt-inhibitor treatment. 28 ETS proteins are transcription factors that can alter the expression of genes that are involved in various biological processes, such as hematopoiesis, cellular proliferation, differentiation, development and apoptosis. 29 ETS1 has long been implied to have a role in hematologic malignancies. 30, 31 Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells revealed recurrent microdeletions targeting ETS1. 32 In addition, analyses of low-risk MDS cases found ETS1 to have tumor-suppressor function as the gene was hypermethylated and showed low expression levels, with various ETS1 targets being downregulation as a result. 33 The protein tyrosine phosphatase STS-1 has recently been shown to interact with CBL, regulating myeloid proliferation in human AML1-ETO. 34 An interaction between VAV3 and EZH2 has previously been revealed for putative homologs in Saccharomyces cerevisiae. 35 Studies have shown that VAV3 has a role in lymphocyte activation and development. 36 Interestingly, genetic deficiency of VAV3 delays the progression of BCR-ABL-positive lymphoblastic leukemia and increases leukemic cell death making the gene a potential therapeutic target. 37 The apparent paradox of opposite regulation of some genes between cell lines and patients may occur for a number of reasons. (1) Artificial introduction of EZH2 dysfunction in sAML cell lines might bring about different effects, compared with EZH2 mutations in less-proliferative MDS cells, while still indicating potential targets. (2) EZH2 expression was overall higher in cell lines compared with patients ( Figure 5, Supplementary Table 4) . The different levels of EZH2 protein may alter the spectrum of function and modify PRC2 activity, as highlighted by the arbitrary role of EZH2 as a tumor suppressor and oncogene. (3) The results indicate that CXXC5, ETS1, STS-1 and VAV3 may not be direct targets of EZH2, but rather fall under the regulatory control of secondary pathways. For example, Viré et al. 38 have shown that the two epigenetic systems of histone and DNA methylation are connected. Thus, DNA methylation could serve as a switch for gene expression, depending on the level of EZH2 activity.
In conclusion, we found a spectrum of concurrent and mutually exclusive mutations of EZH2-positive MDS/MPN patients similar to molecular patterns observed in MDS. Further studies with larger cohorts will reveal how the mutational landscape affects disease phenotype and response to therapy. EZH2 mutations seem to be early events in leukemogenesis, particularly when age-related clonal hematopoiesis genes are not involved. Comparison of Figure 4 . Microarray and qRT-PCR expression data of genes regulated in both patients and cell lines in relation to EZH2 aberration. Genes showing differences between patients depending on EZH2 status in comparison with cell line data; *P ⩽ 0.05; **P ⩽ 0.005; ***P ⩽ 0.0005; mean and standard deviation of microarray average signal intensities and Log2 expression ratios of (i) microarray and (ii) qRT-PCR data (a) expression data of genes with significant ⩾ 2 FC differences between EZH2 wild-type and mutant patients (n = 12 each). (b) Expression data of genes with significant differences between control and shRNA manipulated F-36P cell lines (n = 4 each). (c) Expression data of genes with significant differences between control and shRNA manipulated MOLM-13 cell lines (n = 4 each). (d) Expression data of genes with significant differences between control and shRNA manipulated OCI-M2 cell lines (n = 4 each). Differences between microarray and qRT-PCR data are due to inter-assay variations. Detailed information is given in Supplementary Table 4. patient data with EZH2-downregulated sAML cell lines revealed CXXC5, FAM113B, ETS1, STS-1 and VAV3 expression to be associated with EZH2 mutational status, among other genes with lower expression levels (PM20D2, PRAGMIN, RAB3IL1). Whether these targets are up-or downregulated may depend on initial EZH2 expression and cellular context. At this point, the exact pathway, through which EZH2 may exert regulatory control, remains unknown. Nonetheless, to our knowledge, this is the first study that has uncovered these genes as EZH2 targets in myeloid malignancies. Further study will reveal their precise role in myeloid leukemogenesis. Relative optical densitiy
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EZH2 wild-type EZH2 mutant Figure 5 . Protein blot analysis of F-36P, MOLM-13, OCI-M2 and patient data. Cell lines expressing EZH2-targeting shRNA genes 1 or 2 (sh 1, sh 2) or a nontargeting control shRNA and patient cell samples were lysed and processed via SDS-PAGE and immunoblotted. Histone H3 and GAPDH were used as loading controls. (a) Protein blots show a reduced EZH2 expression in manipulated cells as well as a reduced H3K27 trimethylation. ETS1, STS-1 and VAV3 show upregulation in manipulated cell lines. Marginal downregulation was observed for CXXC5 and FAM113B for manipulated cell lines. (b) Cell line protein blots, semi-quantified using H3 as a reference for H3K27me3 and GAPDH as a reference for all other proteins (c) Protein blots of EZH2 mutant patients #24 (p.N263Qfs*8), 27 (p.K685Rfs*12), 32 (p.K17Sfs*3) and 34 (p.Y292X) show a reduced EZH2 expression, particularly for homozygous patients #27 and 32, and a reduced H3K27me3 expression, compared with EZH2 wild-type patients D and F.
